Evolocumab treatment is associated with early and sustained reductions in low-density cholesterol (LDL-C) over 30 months: final results from the pan-European observational HEYMANS registry
26 August 2022 (08:00 - 19:30)
Organised by:
About the speaker
Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)
4 More presentations in this session
Doctor D. Kannenkeril (Erlangen, DE)
Professor O. Weingaertner (Jena, DE)
Access the full session
The Event
ESC Congress 2022
26 August - 29 August 2022
You may be interested in
Congress Presentation
Congress Presentation
